These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D,L-lactic-co-glycolic acid) versus chitosan microspheres. Jaganathan KS; Rao YU; Singh P; Prabakaran D; Gupta S; Jain A; Vyas SP Int J Pharm; 2005 Apr; 294(1-2):23-32. PubMed ID: 15814228 [TBL] [Abstract][Full Text] [Related]
3. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Gupta RK; Chang AC; Siber GR Dev Biol Stand; 1998; 92():63-78. PubMed ID: 9554260 [TBL] [Abstract][Full Text] [Related]
4. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination. Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180 [TBL] [Abstract][Full Text] [Related]
5. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Waeckerle-Men Y; Groettrup M Adv Drug Deliv Rev; 2005 Jan; 57(3):475-82. PubMed ID: 15560953 [TBL] [Abstract][Full Text] [Related]
6. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Tamber H; Johansen P; Merkle HP; Gander B Adv Drug Deliv Rev; 2005 Jan; 57(3):357-76. PubMed ID: 15560946 [TBL] [Abstract][Full Text] [Related]
7. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B. Jaganathan KS; Singh P; Prabakaran D; Mishra V; Vyas SP J Pharm Pharmacol; 2004 Oct; 56(10):1243-50. PubMed ID: 15482638 [TBL] [Abstract][Full Text] [Related]
8. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Elamanchili P; Diwan M; Cao M; Samuel J Vaccine; 2004 Jun; 22(19):2406-12. PubMed ID: 15193402 [TBL] [Abstract][Full Text] [Related]
9. Aspects of the design and delivery of microparticles for vaccine applications. Jenkins PG; Coombes AG; Yeh MK; Thomas NW; Davis SS J Drug Target; 1995; 3(1):79-81. PubMed ID: 7655826 [TBL] [Abstract][Full Text] [Related]
10. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. Chong CS; Cao M; Wong WW; Fischer KP; Addison WR; Kwon GS; Tyrrell DL; Samuel J J Control Release; 2005 Jan; 102(1):85-99. PubMed ID: 15653136 [TBL] [Abstract][Full Text] [Related]
11. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. Wischke C; Borchert HH; Zimmermann J; Siebenbrodt I; Lorenzen DR J Control Release; 2006 Sep; 114(3):359-68. PubMed ID: 16889866 [TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of novel biodegradable microspheres based on poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies. Mundargi RC; Srirangarajan S; Agnihotri SA; Patil SA; Ravindra S; Setty SB; Aminabhavi TM J Control Release; 2007 May; 119(1):59-68. PubMed ID: 17331611 [TBL] [Abstract][Full Text] [Related]
13. Cationic microparticles consisting of poly(lactide-co-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination. Oster CG; Kim N; Grode L; Barbu-Tudoran L; Schaper AK; Kaufmann SH; Kissel T J Control Release; 2005 May; 104(2):359-77. PubMed ID: 15907586 [TBL] [Abstract][Full Text] [Related]
14. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572 [TBL] [Abstract][Full Text] [Related]
15. Encapsulation of antigen in poly(D,L-lactide-co-glycolide) microspheres protects from harmful effects of γ-irradiation as assessed in mice. Mohanan D; Gander B; Kündig TM; Johansen P Eur J Pharm Biopharm; 2012 Feb; 80(2):274-81. PubMed ID: 22024408 [TBL] [Abstract][Full Text] [Related]
16. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Jain S; O'Hagan DT; Singh M Expert Rev Vaccines; 2011 Dec; 10(12):1731-42. PubMed ID: 22085176 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628 [TBL] [Abstract][Full Text] [Related]
18. In vivo uptake of an experimental microencapsulated diphtheria vaccine following sub-cutaneous immunisation. Peyre M; Fleck R; Hockley D; Gander B; Sesardic D Vaccine; 2004 Jun; 22(19):2430-7. PubMed ID: 15193406 [TBL] [Abstract][Full Text] [Related]
19. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. Pai Kasturi S; Qin H; Thomson KS; El-Bereir S; Cha SC; Neelapu S; Kwak LW; Roy K J Control Release; 2006 Jul; 113(3):261-70. PubMed ID: 16793161 [TBL] [Abstract][Full Text] [Related]